Reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends the provisions of the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It mandates the Food and Drug Administration to publish a report detailing the actions taken under the 2022 Action Plan for Rare Neurodegenerative Diseases, including ALS. The report must also describe the effects of the plan on therapy development and regulatory considerations for ALS and other rare neurodegenerative diseases.

Reauthorizes the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031.

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends the provisions of the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031. It mandates the Food and Drug Administration to publish a report detailing the actions taken under the 2022 Action Plan for Rare Neurodegenerative Diseases, including ALS. The report must also describe the effects of the plan on therapy development and regulatory considerations for ALS and other rare neurodegenerative diseases.